Abstract Number: PB0751
Meeting: ISTH 2021 Congress
Background: The morbidity and mortality of BCR-ABL negative myeloproliferative neoplasms (polycythaemia vera, essential thrombocyhaemia and primary myelofibrosis) is highly dependent on thrombotic complications. In myeloproliferative neoplasia patients circulating platelets are already activated and they secrets higher levels of surface Pselectin and tissue factor. Anti-β2 glycoprotein 1 antibodies (β2GP1) bind to the β2GP1 receptors on the platelet surface, activating them that is important for thrombus formation. Antiphospholipid antibodies activates endothelial cells, whose dysfunction also plays an important role in the pathogenesis of thrombosis in BCR-ABL negative myeloproliferative neoplasia.
Aims: To evalute the antiphospholipid antibodies in relationship P Selectin Glycoprotein Ligand 1 (PSGL1) polymorphism on the development of thrombosis with other risk factors in patients with MPN
Methods: A total of 105 MPN patients were included in this retrospective study. 58 of the MPN patients were diagnosed with essential thrombocythemia (ET), 41 with polycythemia vera (PV), 6 with myelofibrosis (MF). Clinical data about the
development of thrombosis was collected. PSGL1 polymorphisms was determined from peripheral blood samples using PCR method. In electrophoresis the size of A allele was 558 bp, B allele – 528 bp. Data analysis was performed using
“IBM SPSS Statistics 23”. There were two different selective and one confirmatory test for the LA determination. The detection of antibodies against β2-glycoprotein-1 (β2GP1) was performed using a chemiluminescent method. The detection of antibodies against cardiolipin (aCL) was performed ELISA using commercial Aeskulisa Cardiolipin-GM (AESKU.DIAGNOSTICS, Germany).
Results: Arterial thrombotic complications were present in 38 (42.2%) of those with MPN. These patients were diagnosedwith transient ischaemic attack (TIA), ischaemic stroke or myocardial infarction. aPL together with PSGL1 polymorphism were significant more frequently found in arterial thrombosis MPN patients compared with MPN patients who didn’texperienced thrombosis (21.1% and 5.8%; p< 0.029).
Conclusions: Myeloproliferative neoplasm´s patients with antiphospholipid antibodies and PSGL1 polymorphism may have the increased risk of thrombosis development.
To cite this abstract in AMA style:Dambrauskienė R, Gerbutavičius R, Vadeikienė R, Gerbutavičius R, Ugenskienė R, Rudžianskienė M, Juozaitytė E, Remeikienė D, Gerbutavičienė R, Paukštaitienė R. A Role of Possible Synergistic Effect of P Selectin Glycoprotein Ligand 1 Polymorphism and Antiphosholipid Antibodies on Thrombosis in Myeloproliferative Neoplasia Patients [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-role-of-possible-synergistic-effect-of-p-selectin-glycoprotein-ligand-1-polymorphism-and-antiphosholipid-antibodies-on-thrombosis-in-myeloproliferative-neoplasia-patients/. Accessed December 6, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-role-of-possible-synergistic-effect-of-p-selectin-glycoprotein-ligand-1-polymorphism-and-antiphosholipid-antibodies-on-thrombosis-in-myeloproliferative-neoplasia-patients/